Last Updated 08:00:00

CONSUN PHARMA Stock Performance Chart

longbridge loading
Company Encyclopedia
name
CONSUN PHARMA
01681.HK
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, an irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal.
1.392 T
01681.HKMarket value -Rank by Market Cap -/-

Financial Score

13/04/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking8/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE24.98%A
    • Profit Margin31.55%A
    • Gross Margin78.05%A
  • Growth ScoreB
    • Revenue YoY16.29%B
    • Net Profit YoY19.56%B
    • Total Assets YoY14.47%B
    • Net Assets YoY15.11%B
  • Cash ScoreC
    • Cash Flow Margin0.00%D
    • OCF YoY16.29%B
  • Operating ScoreB
    • Turnover0.56B
  • Debt ScoreB
    • Gearing Ratio24.53%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --